Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lonza
Basel, varies, Switzerlandlonza.com ↗
- Ownership
- Public · LONN
- Employees
- ~18500
- Development stage
- Commercial
01
Overview
Lonza does not have its own clinical pipeline but enables the development and commercial manufacturing of hundreds of client molecules. It manufactures the majority of commercially available antibody-drug conjugates globally and supports programs from preclinical through commercial supply. In recent years it has expanded capabilities in cell/gene therapies and mRNA manufacturing. In oncology alone it supported over thirty-two ADC programs in commercial or late-stage clinical supply in 2023.
- Therapeutic areas
- Other
- Modalities
- Monoclonal antibodyAntibody-drug conjugateSmall moleculemRNA-based drugsCell therapyGene therapyBiologicMicrobial therapyRecombinant protein
- Industry
- Contract Manufacturing Organization
02
Partnerships
Vertex Pharmaceuticals (cell therapy manufacturing facility)Multiple major biopharma partnerships for biologics/ADC/commercial drug substance manufacture—often confidential.
03
Financials
- Market cap
- $48M
- Total revenue
- $62.6M
- Enterprise value
- $409.6M
Beyond the preview
Go deeper on Lonza.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lonza.